163 related articles for article (PubMed ID: 28670823)
1. Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
Veldhuijzen NJ; Polman NJ; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2017 Oct; 141(8):1551-1560. PubMed ID: 28670823
[TBL] [Abstract][Full Text] [Related]
2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
3. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
4. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
7. Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV.
Tracht J; Wrenn A; Eltoum IE
Diagn Cytopathol; 2017 Jul; 45(7):580-586. PubMed ID: 28436211
[TBL] [Abstract][Full Text] [Related]
8. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
9. [Performance of combined liquid based cytology and HPV nucleic acid test for detecting cervical precancer among women attending screening].
Jiang MY; Feng RM; Wang L; Li TY; Zhang AA; Cui JF; Pan QJ; Zhang X; Liu ML; Gao F; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):750-756. PubMed ID: 30392339
[No Abstract] [Full Text] [Related]
10. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.
Monsonego J; Cox JT; Behrens C; Sandri M; Franco EL; Yap PS; Huh W
Gynecol Oncol; 2015 Apr; 137(1):47-54. PubMed ID: 25667973
[TBL] [Abstract][Full Text] [Related]
11. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
[TBL] [Abstract][Full Text] [Related]
12. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
13. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
14. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer.
Verhoef VM; Heideman DA; van Kemenade FJ; Rozendaal L; Bosgraaf RP; Hesselink AT; Bekkers RL; Massuger LF; Steenbergen RD; Snijders PJ; Berkhof J; Meijer CJ
Gynecol Oncol; 2014 Oct; 135(1):58-63. PubMed ID: 25111387
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening.
Chatzistamatiou K; Moysiadis T; Moschaki V; Panteleris N; Agorastos T
Gynecol Oncol; 2016 Jul; 142(1):120-127. PubMed ID: 27126005
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
18. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
20. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
